Rapid acting antidepressants in the mTOR pathway: Current evidence
| Autor: | Sumana Chakravarty, Arathy S Mohan, KV Athira |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Time Factors Scopolamine AMPA receptor 03 medical and health sciences 0302 clinical medicine Monoaminergic Rapastinel Animals Humans Medicine PI3K/AKT/mTOR pathway Depressive Disorder Major business.industry Drug discovery Drug Administration Routes TOR Serine-Threonine Kinases General Neuroscience medicine.disease Antidepressive Agents 030104 developmental biology Major depressive disorder Antidepressant Ketamine Metabotropic glutamate receptor 2 business Neuroscience 030217 neurology & neurosurgery Signal Transduction |
| Zdroj: | Brain Research Bulletin. 163:170-177 |
| ISSN: | 0361-9230 |
| DOI: | 10.1016/j.brainresbull.2020.07.022 |
| Popis: | Despite the growing burden of major depressive disorder (MDD) on the society, therapeutic management that is mostly based on the conventional monoaminergic mechanisms, is significantly delimited especially from low response rate and time lag for treatment response; thus, often prolonging the distress for patients. The mechanistic exploration of drug candidates that could exert antidepressant effects rapidly has highlighted the significance of modulating mammalian target of rapamycin (mTOR) pathway in MDD. Fast acting antidepressants acts at different receptors, subunits and sites, including NMDA, AMPA, m1ACh, mGluR2/3 and GluN2B to enhance mTOR function, leading to increase in synaptic protein synthesis, synaptogenesis and spine-remodeling, which in turn contribute to the rapid antidepressant effects. This review focuses on the preclinical and clinical evidences on the fast acting antidepressants that can modulate mTOR pathway. It can be understood that modulating mTOR pathway for rapid onset of antidepressant effect in MDD is not without challenges as some of the drugs have failed in advanced stages of clinical trials. However, considering the recent approval of esketamine as a breakthrough in decades, fast acting antidepressants in the mTOR pathway may have promising prospects in the drug discovery pipeline. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect